Zidovudine with nevirapine for the prevention of HIV mother-to-child transmission reduces nevirapine resistance in mothers from the Western Cape, South Africa

Journal of Medical Virology

Volumn 80, Issue 6, 2008, Pages 942-946

  Van Zyl, G U ^a   Claassen, M ^a   Engelbrecht, S ^a   Laten, J D ^a   Cotton, M F ^b   Theron, G B ^b   Preiser, W ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Antiretroviral drug resistance; HIV; Nevirapine (NVP); Prevention of mother to child transmission; Zidovudine (AZT)

Indexed keywords

NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANALYTIC METHOD; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; GENE SEQUENCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MONOTHERAPY; POLYMERASE CHAIN REACTION; PREVALENCE; RISK; SINGLE DRUG DOSE; SOUTH AFRICA; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DISEASE TRANSMISSION, VERTICAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; INFANT; MUTATION; NEVIRAPINE; PREGNANCY; SOUTH AFRICA; ZIDOVUDINE;

EID: 43249098655     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21157     Document Type: Article

References (17)

1. Arrivé E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, Leroy V, Perre PV, Rouzioux C, Dabis F. 2007. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: A meta-analysis. Int J Epidemiol 36:1009-1021.
2. Centers for Disease Control and Prevention (CDC). 1994. Zidovudine for the prevention of HIV transmission from mother to infant. Morb Mortal Wkly Rep 43:285-287.
3. Dabis F, Bequet L, Ekouevi DK, Viho I, Rouet F, Horo A, Sakarovitch C, Becquet R, Fassinou P, Dequae-Merchadou L, Welffens-Ekra C, Rouzioux C, Leroy V. 2005. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 19:309-318.
4. Eley B. 2006. Addressing the paediatric HIV epidemic: A perspective from the Western Cape Region of South Africa. Trans R Soc Trop Med Hyg 100:19-23.
5. Eshleman SH, Guay LA, Mwatha A, Cunningham SP, Brown ER, Musoke P, Mmiro F, Jackson JB. 2004. Comparison of nevirapine (NVP) resistance in Ugandan women 7 days vs. 6-8weeks after single-dose nvp prophylaxis: HIVNET 012. AIDS Res Hum Retroviruses 20:595-599.
6. Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, Fiscus SA, Mmiro F, Musoke P, Jackson JB, Kumwenda N, Taha T. 2005. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 19:2167-2169.
7. Eshleman SH, Hoover DR, Chen S, Hudelson SE, Guay LA, Mwatha A, Fiscus SA, Mmiro F, Musoke P, Jackson JB, Kumwenda N, Taha T. 2005. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis 192:30-36.
8. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F, Jackson JB. 1999. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354:795-802.
9. Jackson JB, Musoke P, Fleming T, Guay LA, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Owor M, Ducar C, Deseyve M, Mwatha A, Emel L, Duefield C, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Gigliotti M, Bray D, Mmiro F. 2003. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet 362:859-868.
10. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, Bowonwatanuwong C, Kantipong P, Leechanachai P, Ariyadej S, Leenasirimakul P, Hammer S, Lallemant M. 2004. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med 2004. 351:229-240.
11. Lallemant M, Jourdain G, Le Coeur S, Mary JY, Ngo-Giang-Huong N, Koetsawang S, Kanshana S, McIntosh K, Thaineua V. 2004. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med 351:217-228.
12. Lockman S, Shapiro RL, Smeaton LM, Wester C, Thior I, Stevens L, Chand F, Makhema J, Moffat C, Asmelash A, Ndase P, Arimi P, van Widenfelt E, Mazhani L, Novitsky V, Lagakos S, Essex M. 2007. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 356:135-147.
13. McConnell MS, Stringer JS, Kourtis AP, Weidle PJ, Eshleman SH. 2007. Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: Does development of resistance matter? Am J Obstet Gynecol 197:556-563.
14. Plantier JC, Dachraoui R, Lemee V, Gueudin M, Borsa-Lebas F, Caron F, Simon F. 2005. HIV-1 resistance genotyping on dried serum spots. AIDS 19:391-397.
15. Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, Chotpitayasunondh T, Chearskul S, Roongpisuthipong A, Chinayon P, Karon J, Mastro TD, Simonds RJ. 1999. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 353:773-780.
16. Thior I, Lockman S, Smeaton LM, Shapiro RL, Wester C, Heymann SJ, Gilbert PB, Stevens L, Peter T, Kim S, van Widenfelt E, Moffat C, Ndase P, Arimi P, Kebaabetswe P, Mazonde P, Makhema J, McIntosh K, Novitsky V, Lee TH, Marlink R, Lagakos S, Essex M. 2006. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana: A randomized trial: The Mashi Study. JAMA 296:794-805.
17. Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P. 2007. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 1:CD003510.